What is Codexis Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Codexis's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Codexis's Operating Income for the
three
months ended in Dec. 2023 was $ 0.28 Mil. Codexis's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate Codexis's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Codexis Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Codexis (NAS:CDXS) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Codexis's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $0.28 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $12.24 Mil.
Codexis's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate Codexis's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Codexis Inc has enough cash to cover all of its debt. Its financial situation is stable.
Codexis (Codexis) Business Description
Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood, CA, USA, 94063
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products. The firm's products and services include Screening and Evolution services, Enzymes, Screening Kits. It also develops protein engineering and biocatalyst platforms such as Codeevolver, Ketoreductases, Transminases, Imine reductases, etc. The company operates in two business segments namely Performance Enzymes and Novel Biotherapeutics. It generates maximum revenue from the Performance Enzymes segment. Geographically, it derives a majority of revenue from the APAC.
Executives
| Byron L Dorgan |
director |
C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
| Kevin Norrett |
officer: Chief Operating Officer |
C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
| Margaret Nell Fitzgerald |
officer: See Remarks |
ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070 |
| Sriram Ryali |
officer: Chief Financial Officer |
C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO CA 94306 |
| Stephen George Dilly |
director, officer: See Remarks |
C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
| John J Nicols |
director, officer: President and CEO |
ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801 |
| H Stewart Parker |
director |
|
| Rahul Singhvi |
director |
246 HOLLY DRIVE, CHALFONT PA 18914 |
| Dennis P Wolf |
director |
1101 EAST MEADOW DR, PALO ALTO CA 94303 |
| Patrick Y Yang |
director |
C/O GENENTECH INC, 1 DNA WAY,MS 49,ATTN:K.STRAND OR J.BERRY, SOUTH SAN FRANCISCO CA 94080-4990 |
| Bernard J Kelley |
director |
|
| Esther Martinborough |
director |
C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
| Jennifer Aaker |
director |
C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
| Alison Moore |
director |
C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Thomas R Baruch |
director |
1 LETTERMAN DRIVE, BUILDING C, SUITE CM500, SAN FRANCISCO CA 94129 |
Codexis (Codexis) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDXS has been successfully added to your 